Marker Therapeutics, Inc.

Tagged: clinical update

Marker Therapeutics Announces Clinical Update at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019

Marker Therapeutics announces updated data from four clinical trials using the Company’s multi-antigen targeted T cell (MultiTAA) therapies.
Read More

TapImmune CEO Provides Update on Corporate Activity and Progression of Clinical Programs

I am pleased to provide this update to existing shareholders and interested potential shareholders SEATTLE–(BUSINESS WIRE)– TapImmune is a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious disease.
Read More